Skip to main content

Advertisement

Fig. 2 | Cardiovascular Diabetology

Fig. 2

From: Everolimus-eluting bioresorbable scaffolds for treatment of coronary artery disease in patients with diabetes mellitus: the midterm follow-up of the prospective ABSORB DM Benelux study

Fig. 2

Shown are the 2-year Kaplan–Meier estimates of each of the composites of the endpoints and scaffold thrombosis. The safety outcomes regarding any myocardial infarction, target vessel myocardial infarction and scaffold thrombosis were favourable. For scaffold thrombosis an explicit difference has been made between definite (blue) and probable (red) both accounting for 0.7% of the total 1.4%. There were no occurrences of late or very late definite or probable scaffold thrombosis. MI myocardial infarction, TVR target vessel revascularization, TLR target lesion revascularization, ScT scaffold thrombosis

Back to article page